Cargando…

Levocarnitine regulates the growth of angiotensin II-induced myocardial fibrosis cells via TIMP-1

This study aimed to explore the effects of tissue inhibitor of metalloproteinases‐1 (TIMP‐1) on levocarnitine (LC)-mediated regulation of angiotensin II (AngII)-induced myocardial fibrosis (MF) and its underlying mechanisms. H9C2 cells were treated with AngII for 24 h to induce fibrosis. The cells w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shu, Jin, Shi, Jue, Gu, Yiwen, Deng, Lei, Zhao, Chen, Wu, Chun, Zhao, Jiachen, Wang, Haiya, Jin, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	De Gruyter 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922061/ https://www.ncbi.nlm.nih.gov/pubmed/36816804 http://dx.doi.org/10.1515/biol-2022-0554

Ejemplares similares

Matrix metalloproteinase 3 regulates angiotensin II-induced myocardial fibrosis cell viability, migration and apoptosis
por: Shu, Jin, et al.
Publicado: (2021)

Significance of Levocarnitine Treatment in Dialysis Patients
por: Takashima, Hiroyuki, et al.
Publicado: (2021)

Effects of Levocarnitine Treatment on the Cardiac Function in Hemodialysis Patients
por: Maruyama, Takashi, et al.
Publicado: (2018)

Effect of levocarnitine administration in patients with chronic liver disease
por: Ohashi, Kazuki, et al.
Publicado: (2020)

Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis
por: Hiramatsu, Akira, et al.
Publicado: (2019)

High-Flux Hemodialysis and Levocarnitine in the Treatment of Severe Valproic Acid Intoxication
por: Temel, V., et al.
Publicado: (2013)

MON-065 Prevention of 6-Mercaptopurine-Induced Hypoglycemia by Levocarnitine Replacement
por: Torchinsky, Michael Yuri, et al.
Publicado: (2020)

Recruitment of macrophages from the spleen contributes to myocardial fibrosis and hypertension induced by angiotensin II
por: Wang, Ning-Ping, et al.
Publicado: (2017)

Antibody therapy can enhance AngiotensinII-induced myocardial fibrosis
por: Rosin, Nicole L, et al.
Publicado: (2014)

Disparate effects of MMP and TIMP modulation on coronary atherosclerosis and associated myocardial fibrosis
por: Kremastiotis, Georgios, et al.
Publicado: (2021)

Topical Delivery of Levocarnitine to the Cornea and Anterior Eye by Thermosensitive in-situ Gel for Dry Eye Disease
por: Ma, Baorui, et al.
Publicado: (2021)

Fibulin-2 is Essential for Angiotensin II-Induced Myocardial Fibrosis Mediated by Transforming Growth Factor (TGF)-β
por: Khan, Shaukat A., et al.
Publicado: (2016)

Levocarnitine for valproate-induced hyperammonemia in the psychiatric setting: A case series and literature review
por: Brown, Lauren M., et al.
Publicado: (2018)

Levocarnitine for pegaspargase‐induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia
por: Schulte, Rachael, et al.
Publicado: (2021)

The Efficacy of Levocarnitine Treatment in Relieving Fatigue in Patients with Cirrhosis but without Overt Hepatic Encephalopathy
por: Abe, Kazumichi, et al.
Publicado: (2021)

Surgery-Induced Hippocampal Angiotensin II Elevation Causes Blood-Brain Barrier Disruption via MMP/TIMP in Aged Rats
por: Li, Zhengqian, et al.
Publicado: (2016)

Improving vagal activity ameliorates cardiac fibrosis induced by angiotensin II: in vivo and in vitro
por: Liu, Jin-Jun, et al.
Publicado: (2015)

The sirtuin 6 prevents angiotensin II-mediated myocardial fibrosis and injury by targeting AMPK-ACE2 signaling
por: Zhang, Zhen-Zhou, et al.
Publicado: (2017)

Angiotensin II Receptor Blocker Attenuates Intrarenal Renin-Angiotensin-System and Podocyte Injury in Rats with Myocardial Infarction
por: Wen, Zhu-zhi, et al.
Publicado: (2013)

Hepatic Lipocytes, TIMP-1 and Liver Fibrosis
Publicado: (1994)

Hepatic Lipocytes, TIMP-1 and Liver Fibrosis
por: Arthur, Michael J P, et al.
Publicado: (1994)

Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients
por: Graziano, F, et al.
Publicado: (2002)

A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders
por: Geier, David A., et al.
Publicado: (2011)

Attenuation of myocardial fibrosis with curcumin is mediated by modulating expression of angiotensin II AT1/AT2 receptors and ACE2 in rats
por: Pang, Xue-Fen, et al.
Publicado: (2015)

Modulation of angiotensin II signaling in the prevention of fibrosis
por: Murphy, Amanda M, et al.
Publicado: (2015)

Effects of Levocarnitine on Brachial-Ankle Pulse Wave Velocity in Hemodialysis Patients: A Randomized Controlled Trial
por: Higuchi, Terumi, et al.
Publicado: (2014)

Levocarnitine Improves AlCl(3)-Induced Spatial Working Memory Impairment in Swiss albino Mice
por: Al-Amin, Md. Mamun, et al.
Publicado: (2019)

Skeletal muscle volume loss among liver cirrhosis patients receiving levocarnitine predicts poor prognosis
por: Fujita, Masashi, et al.
Publicado: (2020)

Levistilide A reverses rat hepatic fibrosis by suppressing angiotensin II-induced hepatic stellate cells activation
por: Li, Shu, et al.
Publicado: (2020)

Angiotensin II Differentially Induces Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Production and Disturbs MMP/TIMP Balance
por: Yaghooti, Hamid, et al.
Publicado: (2010)

Effect of endostatin overexpression on angiotensin II-induced cardiac hypertrophy in rats
por: Dai, You-Jin, et al.
Publicado: (2019)

Levocarnitine Supplementation Suppresses Lenvatinib-Related Sarcopenia in Hepatocellular Carcinoma Patients: Results of a Propensity Score Analysis
por: Okubo, Hironao, et al.
Publicado: (2021)

The effect of levocarnitine supplementation on dialysis-related hypotension: A systematic review, meta-analysis, and trial sequential analysis
por: Chewcharat, Api, et al.
Publicado: (2022)

Levocarnitine Protects H9c2 Rat Cardiomyocytes from H(2)O(2)-induced Mitochondrial Dysfunction and Apoptosis
por: Mao, Cui-Ying, et al.
Publicado: (2014)

Stachydrine Ameliorates Cardiac Fibrosis Through Inhibition of Angiotensin II/Transformation Growth Factor β1 Fibrogenic Axis
por: Liu, Xiao, et al.
Publicado: (2019)

MicroRNA‐503 promotes angiotensin II‐induced cardiac fibrosis by targeting Apelin‐13
por: Zhou, Yuhong, et al.
Publicado: (2016)

Angiotensin II mediates hypertensive cardiac fibrosis via an Erbb4-IR-dependent mechanism
por: Li, Jian-Chun, et al.
Publicado: (2023)

Phosphatidylethanolamine aggravates Angiotensin II-induced atrial fibrosis by triggering ferroptosis in mice
por: Huang, Fangze, et al.
Publicado: (2023)

SMOC1 silencing suppresses the angiotensin II-induced myocardial fibrosis of mouse myocardial fibroblasts via affecting the BMP2/Smad pathway
por: Wang, Yize, et al.
Publicado: (2018)

Effect of Levocarnitine on the Therapeutic Efficacy of Conventional Therapy in Children with Dilated Cardiomyopathy: Results of a Randomized Trial in 29 Children
por: Wang, Yuwen, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sgsgtj4nhk7llop707fm5ac0v2